Compare Jones Lang LaSalle Inc (JLL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Neurocrine Biosciences Inc — how do they compare? Jones Lang LaSalle Inc trades at $362.41 (market cap $16.44B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Jones Lang LaSalle Inc and Neurocrine Biosciences Inc are close in size by market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| JLL | NBIX | |
|---|---|---|
Market Cap | $16.44B | $16.76B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $185.50 |
52-Week Low | $280.16 | $123.10 |
Enterprise Value | $19.20B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $362.38, down 0.36% on the day, near its 52-week high. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M, and analysts project further growth in 2026. Positive sentiment is driven by strong Q2 2026 results and AI-related real estate demand highlighted in recent company research.
Outlook remains positive with a consensus price target of $391.50, though risks include market volatility and execution challenges in capital markets. The stock offers growth potential from expanding profit margins and strategic positioning in AI-impacted real estate sectors, balanced by economic sensitivity.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
